What will we define as a success for any given stem cell biotech? In academia, even if we do pre-clinical, translational kind of biomedical sciences, we still do not often think about what it takes to succeed in industry. Even if we very much want our research to make a difference for patients, do we …
For those of us conducting stem cell research, especially human stem cell research, I don’t have to tell you how expensive it is. Even just doing pre-clinical or basic science research costs a fortune. When you start talking about the kind of pre-clinical research specifically designed to get in the near future to a Phase …
The valley of death: stem cells, biotechs, and money Read More »
Who’s who in the iPS cell field? In this post, I examine the people, journals, places, funding agencies, and companies that are the leaders in the iPS cell field. I start with publishing. Last year we did a post on publishing trends in the iPS cell field. It suggested that the iPS cell field was exploding …
Who’s who in iPS cells: scientists, journals, funding agencies, countries, and biotechs Read More »
What’s going on these days with biotech companies working on stem cell-based products? Geron’s and Advanced Cell Technology (ACT)’s FDA-approved trials presumably continue. As expected, no news yet. It’s too soon. Two important questions regarding both these companies are (1) did they apply for CIRM funding and (2) if so, how did the review process …
Stem cell biotech updates: Geron, ACT, Neuralstem, Pfizer Read More »
If you remember Monty Python, then you probably recall John Cleese. We’ll start with Cleese’s stem cell baloney. Not spam. Secret to eternal youth? John Cleese extols virtues of stem cell treatment, The Guardian. I’ve written before about John Cleese’s stem cell anti-aging efforts. As I told the author of The Guardian piece, I love …
Utah appears ready to pass a new stem cell law that would explicitly allow clinical use of non-FDA-approved placental cell drug therapies in the state. Bill 199 seems likely to set up a conflict with the FDA that may land in court. The key part of the bill says: “A health care provider whose scope …
Vertex Pharmaceuticals has a lot going for it right now on the cell therapy front. For instance, they have the strongest type 1 diabetes cell therapy pipeline after some recent acquisitions. Still it’s not a simple matter to succeed in the cell therapy space even with one therapy for one targeted disease. Trials are tough …
Weekly reads: Vertex, stem cells for MS, Athersys, 900-day paper review at Nature Read More »
Would you guess that Elon Musk might be into using biotechnology in a high-profile way to try to live far longer than usual, say to age 150? That would have been my assumption. There are countless things about Elon Musk that I really don’t like. I also don’t see many issues on which we are …
I found something Elon Musk & I agree on: pushing back on anti-aging bluster Read More »
Readers of The Niche have asked me many questions about stem cells for autoimmune disease but the puzzle of why women get these conditions more often than men hasn’t come up before here. For instance, why is MS so much more common in women than men? It’s remained somewhat of a mystery over the years. …
A reader of The Niche recently asked me, “What about stem cells for deafness?” It’s a great question and, as they pointed out, stem cells for vision loss gets much more attention. I’ve covered the translational progress of stem cells to treat many diseases but there has been less progress for deafness in the regenerative …